Correction to: Adv Ther (2019) 36:1786–1811 https://doi.org/10.1007/s12325-019-00985-8

In this article, the drug name in figure 2 is given as Atorvastatin 20 mg incorrectly. The correct Fig. 2 is given below.

Fig. 2
figure 2

Evolution of LDL-C values in case 2 with lomitapide therapy. Upper panel shows mean interval LDL-C levels for patient 2. Middle panel shows lomitapide dose changes over time. Lower panel shows corresponding ALT (closed circles) and AST (open squares) levels over the same period. Dotted line on upper panel shows EAS targets for LDL-C levels in children with HoFH. Dotted line on lower panel indicates 3× upper limit of normal for LFTs; ALT alanine aminotransferase, AST aspartate aminotransferase, EAS European Atherosclerosis Society, HoFH homozygous familial hypercholesterolaemia, LDL-C low-density lipoprotein cholesterol, LFTs liver function tests, Q2W every 2 weeks, ULN upper limit of normal

Full size image

The Tables 1 and 2 consists few errors in published article. The correct Tables 1 and 2 are given below.

Table 1 Individual data for the 11 patients
Full size table

In the result section of abstract, text has been updated. The incorrect text is “In the 11 cases, mean baseline LDL-C was 419 ± 74.6 mg/dL and was markedly reduced by lomitapide to a nadir of 176.7 ± 46.3 mg/dL (58.4 ± 6.8% decrease). Six patients achieved recommended target levels for children below 135 mg/dL, five of whom had LA frequency reduced.”

The correct text is “In the 11 cases, mean baseline LDL-C was 422 ± 245.4 mg/dL and was markedly reduced by lomitapide to a nadir of 192.2 ± 163.2 mg/dL (56.7 ± 21.7% decrease). Six patients achieved recommended target levels for children below 135 mg/dL, three of whom had LA frequency reduced and a further three stopped LA.”

In the section of Summary of the Case Series, text has been updated. The incorrect text is “Table 2 provides summary descriptive statistics for all 11 patients. Baseline LDL-C was 419.9 ± 74.6 mg/dL. The mean at nadir was 176.7 ± 46.3 mg/dL, representing a 58.4 ± 6.8% reduction in LDL-C. Note that patients 9–11 had modest decreases in LDL-C levels (patient 9 was treated to reduce LA frequency, and patients 10 and 11 had compliance issues). These LDL-C reductions were achieved with a mean dose of lomitapide 24.5 ± 4.3 mg/day over a mean period of 20.0 ± 2.9 months.”

Table 2 Summary data for the 11 patients
Full size table

The correct text is “Table 2 provides summary descriptive statistics for all 11 patients. Baseline LDL-C was 422.7 ± 245.4 mg/dL. The mean at nadir was 192.2 ± 163.2 mg/dL, representing a 56.7 ± 21.7% reduction in LDL-C. Note that patients 9–11 had modest decreases in LDL-C levels (patient 9 was treated to reduce LA frequency, and patients 10 and 11 had compliance issues). These LDL-C reductions were achieved with a mean dose of lomitapide 25.0 ± 13.8 mg/day over a mean period of 20.0 ± 2.9 months.”